OBJECTIVE: Xpert MTB/RIF ('Xpert') and urinary lateral-flow lipoarabinomannan (LF-LAM) assays offer rapid tuberculosis (TB) diagnosis. This study evaluated the cost-effectiveness of novel diagnostic algorithms utilizing combinations of Xpert and LF-LAM for the detection of active TB among people living with HIV. DESIGN: Cost-effectiveness analysis using data from a comparative study of LF-LAM and Xpert, with a target population of HIV-infected individuals with signs/symptoms of TB in Uganda. METHODS: A decision-analysis model compared multiple strategies for rapid TB diagnosis:sputum smear-microscopy; sputum Xpert; smear-microscopy combined with LF-LAM; and Xpert combined with LF-LAM. Primary outcomes were the costs and DALY's averted for each algorithm. Cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Compared with an algorithm of Xpert testing alone, the combination of Xpert with LF-LAM was considered highly cost-effective (ICER $57/DALY-averted) at a willingness to pay threshold of Ugandan GDP per capita. Addition of urine LF-LAM testing to smear-microscopy was a less effective strategy than Xpert replacement of smear-microscopy, but was less costly and also considered highly cost-effective (ICER $33 per DALY-averted) compared with continued usage of smear-microscopy alone. Cost-effectiveness of the Xpert plus LF-LAM algorithm was most influenced by HIV/ART costs and life-expectancy of patients after TB treatment. CONCLUSION: The addition of urinary LF-LAM to TB diagnostic algorithms for HIV-infected individuals is highly cost-effective compared with usage of either sputum smear-microscopy or Xpert alone.
OBJECTIVE: Xpert MTB/RIF ('Xpert') and urinary lateral-flow lipoarabinomannan (LF-LAM) assays offer rapid tuberculosis (TB) diagnosis. This study evaluated the cost-effectiveness of novel diagnostic algorithms utilizing combinations of Xpert and LF-LAM for the detection of active TB among people living with HIV. DESIGN: Cost-effectiveness analysis using data from a comparative study of LF-LAM and Xpert, with a target population of HIV-infected individuals with signs/symptoms of TB in Uganda. METHODS: A decision-analysis model compared multiple strategies for rapid TB diagnosis:sputum smear-microscopy; sputum Xpert; smear-microscopy combined with LF-LAM; and Xpert combined with LF-LAM. Primary outcomes were the costs and DALY's averted for each algorithm. Cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Compared with an algorithm of Xpert testing alone, the combination of Xpert with LF-LAM was considered highly cost-effective (ICER $57/DALY-averted) at a willingness to pay threshold of Ugandan GDP per capita. Addition of urine LF-LAM testing to smear-microscopy was a less effective strategy than Xpert replacement of smear-microscopy, but was less costly and also considered highly cost-effective (ICER $33 per DALY-averted) compared with continued usage of smear-microscopy alone. Cost-effectiveness of the Xpert plus LF-LAM algorithm was most influenced by HIV/ART costs and life-expectancy of patients after TB treatment. CONCLUSION: The addition of urinary LF-LAM to TB diagnostic algorithms for HIV-infected individuals is highly cost-effective compared with usage of either sputum smear-microscopy or Xpert alone.
Authors: L E A Kivihya-Ndugga; M R A van Cleeff; W A Githui; L W Nganga; D K Kibuga; J A Odhiambo; Paul R Klatser Journal: Int J Tuberc Lung Dis Date: 2003-12 Impact factor: 2.373
Authors: Neil A Martinson; Alan Karstaedt; W D Francois Venter; Tanvier Omar; Peter King; Tumi Mbengo; Else Marais; James McIntyre; Richard E Chaisson; Martin Hale Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti Journal: PLoS One Date: 2009-09-25 Impact factor: 3.240
Authors: Stephanie Bjerrum; Ian Schiller; Nandini Dendukuri; Mikashmi Kohli; Ruvandhi R Nathavitharana; Alice A Zwerling; Claudia M Denkinger; Karen R Steingart; Maunank Shah Journal: Cochrane Database Syst Rev Date: 2019-10-21
Authors: A Andama; D Jaganath; R Crowder; L Asege; M Nakaye; D Katumba; S Mwebe; F Semitala; W Worodria; M Joloba; S Mohanty; A Somoskovi; A Cattamanchi Journal: Diagn Microbiol Infect Dis Date: 2019-09-04 Impact factor: 2.803
Authors: Anil Pooran; Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Lawrence Mwenge; Farirai Mutenherwa; Paul Lecesse; John Metcalfe; Hojoon Sohn; Michael Hoelscher; Alex Pym; Jonny Peter; David Dowdy; Keertan Dheda Journal: Lancet Glob Health Date: 2019-06 Impact factor: 26.763
Authors: Swe Swe Thit; Ne Myo Aung; Zaw Win Htet; Mark A Boyd; Htin Aung Saw; Nicholas M Anstey; Tint Tint Kyi; David A Cooper; Mar Mar Kyi; Josh Hanson Journal: BMC Med Date: 2017-08-04 Impact factor: 8.775
Authors: T I Armina Padmasawitri; Gerardus W Frederix; Bachti Alisjahbana; Olaf Klungel; Anke M Hövels Journal: PLoS One Date: 2018-05-09 Impact factor: 3.240
Authors: S Orlando; I Triulzi; F Ciccacci; I Palla; L Palombi; M C Marazzi; M Giuliano; M Floridia; S Mancinelli; E Mutemba; G Turchetti Journal: PLoS One Date: 2018-07-19 Impact factor: 3.240
Authors: Max W Adelman; Deborah A McFarland; Mulugeta Tsegaye; Abraham Aseffa; Russell R Kempker; Henry M Blumberg Journal: Open Forum Infect Dis Date: 2017-12-23 Impact factor: 3.835